Robert Lisac
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Robert Lisac has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Jacob A. Schwartzman
Oregon Health & Science University, Portland, OR
4 shared publications Lina Gao
OHSU Knight Cancer Institute, Portland, OR
4 shared publicationsJoshua Urrutia
OHSU Knight Cancer Institute, Portland, OR
3 shared publicationsCarly King
Oregon Health & Science University, Portland, OR
2 shared publicationsDaniel Coleman
Oregon Health & Science University, Portland, OR
2 shared publicationsJosha Woodward
OHSU Knight Cancer Institute, Portland, OR
2 shared publications
Latest Publications
- 7 September 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (12) , e32045
Moyamoya Syndrome in Patients With Down Syndrome and Acute Lymphoblastic Leukemia
Moyamoya syndrome (MMS) is a chronic vasculopathy characterized by progressive stenosis of intracerebral arteries, leading to an increased risk of stroke. Children with Down syndrome (DS) are at an increased risk of co‐occurring medical conditions, including MMS and leukemia. We report four patients with the triad of DS, MMS, and acute lymphoblastic leukemia (ALL). Two patients had a diagnosis of MMS prior to developing ALL, whereas two were diagnosed with MMS during ALL therapy. This series highlights the need to remain cognizant of MMS in patients with DS and ALL, particularly in those with acute neurologic changes.
- 7 September 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (12) , e32045
Moyamoya Syndrome in Patients With Down Syndrome and Acute Lymphoblastic Leukemia
Moyamoya syndrome (MMS) is a chronic vasculopathy characterized by progressive stenosis of intracerebral arteries, leading to an increased risk of stroke. Children with Down syndrome (DS) are at an increased risk of co‐occurring medical conditions, including MMS and leukemia. We report four patients with the triad of DS, MMS, and acute lymphoblastic leukemia (ALL). Two patients had a diagnosis of MMS prior to developing ALL, whereas two were diagnosed with MMS during ALL therapy. This series highlights the need to remain cognizant of MMS in patients with DS and ALL, particularly in those with acute neurologic changes.
- 30 July 2025
- Published by Wiley in American Journal of Hematology
- Vol. 100 (10) , 1779-1791
Eculizumab is Associated With Increased Infection Rates and Infection Related Mortality in Children With Thrombotic Microangiopathy After HCT
Complement C5 inhibition can be used to treat hematopoietic cell transplant‐associated thrombotic microangiopathy (TA‐TMA) but may impact infectious organism clearance, impeding opsonization and lysis. The infectious risks of eculizumab exposure after hematopoietic cell transplant (HCT) are unknown. In this single center, retrospective case–control study, we included allogeneic HCT recipients transplanted from January 2019 to January 2023. All patients with TA‐TMA treated with eculizumab from day 14–180 post HCT were identified as cases. Controls were matched using an exact matching procedure on maximum grade 3–4 acute GVHD and intensive care unit admission. Cases and controls were matched on index date (first day of eculizumab therapy), and infections from 1 year of index date were captured. Among 31 pairs (62 patients), the rate of bacteremia was 8.49 times higher (95% CI 4.4, 16.4), tissue specific bacterial infections 6.22 times higher (95% CI 2.28, 17.17), and viral infections 3.16 times higher (95% CI 1.90, 5.25) in eculizumab exposed children compared to matched controls. After adjusting for the number of immune suppressive medications, steroid days exposed, and steroid refractory GVHD, all infection rates remained significantly higher among eculizumab exposed patients. In sensitivity models excluding an outlier and altering the study follow up time to 3 and 6 months, rates of infections remained significantly higher in the eculizumab cohort. Infection related mortality was significantly higher in the eculizumab exposed patients than controls; 1‐yr mortality was 45% vs 19% respectively. This study suggests infectious complications are increased with eculizumab treatment in the HCT setting, though additional studies are needed to validate these findings.
- 30 July 2025
- Published by Wiley in American Journal of Hematology
- Vol. 100 (10) , 1779-1791
Eculizumab is Associated With Increased Infection Rates and Infection Related Mortality in Children With Thrombotic Microangiopathy After HCT
Complement C5 inhibition can be used to treat hematopoietic cell transplant‐associated thrombotic microangiopathy (TA‐TMA) but may impact infectious organism clearance, impeding opsonization and lysis. The infectious risks of eculizumab exposure after hematopoietic cell transplant (HCT) are unknown. In this single center, retrospective case–control study, we included allogeneic HCT recipients transplanted from January 2019 to January 2023. All patients with TA‐TMA treated with eculizumab from day 14–180 post HCT were identified as cases. Controls were matched using an exact matching procedure on maximum grade 3–4 acute GVHD and intensive care unit admission. Cases and controls were matched on index date (first day of eculizumab therapy), and infections from 1 year of index date were captured. Among 31 pairs (62 patients), the rate of bacteremia was 8.49 times higher (95% CI 4.4, 16.4), tissue specific bacterial infections 6.22 times higher (95% CI 2.28, 17.17), and viral infections 3.16 times higher (95% CI 1.90, 5.25) in eculizumab exposed children compared to matched controls. After adjusting for the number of immune suppressive medications, steroid days exposed, and steroid refractory GVHD, all infection rates remained significantly higher among eculizumab exposed patients. In sensitivity models excluding an outlier and altering the study follow up time to 3 and 6 months, rates of infections remained significantly higher in the eculizumab cohort. Infection related mortality was significantly higher in the eculizumab exposed patients than controls; 1‐yr mortality was 45% vs 19% respectively. This study suggests infectious complications are increased with eculizumab treatment in the HCT setting, though additional studies are needed to validate these findings.
- Open Access
- 1 June 2021
- Published by Elsevier in Medical Mycology Case Reports
- Vol. 32, 10-13
Allergic fungal rhinosinusitis presenting with intracranial spread along large sphenoidal emissary foramen
- 1 June 2021
- Published by Elsevier in Medical Mycology Case Reports
- Vol. 32, 10-13
Open AccessAllergic fungal rhinosinusitis presenting with intracranial spread along large sphenoidal emissary foramen
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e16538
Androgen content and BET bromodomain proteins influence enzalutamide agonism of mutant F876L androgen receptor.
E16538 Background: One emergent resistance mechanism to medical castration is intratumoral androgen synthesis that activates the androgen receptor (AR). This insight led to the development of the AR antagonist enzalutamide. One enzalutamide resistance mechanism is AR F876L mutations that lead to enzalutamide agonism in some cases. However, mechanisms that contribute to the agonist switch have not been fully clarified, and there are no therapies to block AR F876L. Methods: We usedenzalutamide-resistant cell lines harboring AR F876L mutations to determine mechanisms that contribute to enzalutamide activation of mutant F876L AR. Results: Using these cell line models, we determined that cellular androgen content influences enzalutamide agonism of mutant F876L AR. Further, enzalutamide treatment of AR F876L expressing cell lines recapitulated the effects of androgen activation of F876L AR or wild-type AR. Because the BET bromodomain inhibitor JQ1 was previously shown to block androgen activation of wild-type AR, we tested JQ1 in AR F876L-expressing CRPC models. We determined that JQ1 suppressed androgen or enzalutamide activation of mutant F876L AR and suppressed growth of mutant F876L AR CRPC tumors in vivo, demonstrating a new strategy to treat tumors harboring this mutation. Conclusions: Our data demonstrate that androgens interfere with enzalutamide-induced agonism of F876L mutant AR. Because androgens persist in enzalutamide-resistant CRPC, AR activation by androgens, rather than enzalutamide, may explain why enzalutamide discontinuation does not lead to anti-androgen withdrawal effects clinically. Further, our results provide a cautionary note on therapeutic efforts to deplete androgens concomitantly with enzalutamide treatment as this may accentuate AR agonism by enzalutamide in tumors harboring AR F876L mutations. Finally, targeting BET bromodomain proteins is a promising strategy to suppress mutant AR F876L function irrespective of whether the AR agonist is androgens or enzalutamide.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e16538
Androgen content and BET bromodomain proteins influence enzalutamide agonism of mutant F876L androgen receptor.
E16538 Background: One emergent resistance mechanism to medical castration is intratumoral androgen synthesis that activates the androgen receptor (AR). This insight led to the development of the AR antagonist enzalutamide. One enzalutamide resistance mechanism is AR F876L mutations that lead to enzalutamide agonism in some cases. However, mechanisms that contribute to the agonist switch have not been fully clarified, and there are no therapies to block AR F876L. Methods: We usedenzalutamide-resistant cell lines harboring AR F876L mutations to determine mechanisms that contribute to enzalutamide activation of mutant F876L AR. Results: Using these cell line models, we determined that cellular androgen content influences enzalutamide agonism of mutant F876L AR. Further, enzalutamide treatment of AR F876L expressing cell lines recapitulated the effects of androgen activation of F876L AR or wild-type AR. Because the BET bromodomain inhibitor JQ1 was previously shown to block androgen activation of wild-type AR, we tested JQ1 in AR F876L-expressing CRPC models. We determined that JQ1 suppressed androgen or enzalutamide activation of mutant F876L AR and suppressed growth of mutant F876L AR CRPC tumors in vivo, demonstrating a new strategy to treat tumors harboring this mutation. Conclusions: Our data demonstrate that androgens interfere with enzalutamide-induced agonism of F876L mutant AR. Because androgens persist in enzalutamide-resistant CRPC, AR activation by androgens, rather than enzalutamide, may explain why enzalutamide discontinuation does not lead to anti-androgen withdrawal effects clinically. Further, our results provide a cautionary note on therapeutic efforts to deplete androgens concomitantly with enzalutamide treatment as this may accentuate AR agonism by enzalutamide in tumors harboring AR F876L mutations. Finally, targeting BET bromodomain proteins is a promising strategy to suppress mutant AR F876L function irrespective of whether the AR agonist is androgens or enzalutamide.
- 1 August 2015
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 75 (15_Supplem) , 3592
Abstract 3592: Androgens interfere with enzalutamide agonism of mutant F876L androgen receptor
Multiple lines of evidence demonstrate that castration-resistant prostate cancers (CRPCs) remain reliant on androgens that activate the androgen receptor (AR). Treatment with the novel anti-androgen enzalutamide improves both progression-free and overall survival in CRPC patients (Beer, 2014, Scher, 2012). However, progression is universal. Recently, F876L mutations in the AR ligand binding domain have been described (Balbas, 2013, Korpal, 2013, Joseph, 2013). This mutation confers resistance to enzalutamide treatment and in some cases converts enzalutamide to an AR agonist in pre-clinical studies (Balbas, 2013, Korpal, 2013, Joseph, 2013). Clinical studies demonstrate that ∼10% of patients harbor F876L mutations after treatment with novel anti-androgens (Joseph, 2013). However, anti-androgen withdrawal effects (PSA responses) after discontinuing enzalutamide are rarely seen clinically (Rodriguez-Vida, 2014). An enzalutamide-resistant cell line was developed after chronic treatment of LNCaP cells in vivo. We found that this resistant cell line was dependent on AR expression for survival and that this cell line harbored an AR F876L mutation. When these resistant cells were cultured in complete serum, enzalutamide treatment did not lead to agonistic effects. However, enzalutamide treatment of these resistant cells or cell lines with ectopic expression of AR F876L cultured in androgen-depleted serum led to a significant agonistic effect - an effect that was attenuated by the addition of androgens to culture. Finally, prior work and our own demonstrated that F876L mutant and wild-type AR activate similar pathways (Joseph, 2013). Therefore, we determined if suppression of previously described transcriptional co-activators of wild-type AR also blocked AR F876L function. We found several targetable AR co-activators that met that standard. Our data demonstrate that androgens interfere with enzalutamide-induced agonism of F876L mutant AR. Because androgens persist in enzalutamide-resistant CRPC, AR activation by androgens, rather than enzalutamide, may explain why enzalutamide discontinuation does not lead to anti-androgen withdrawal effects clinically. Further, our results provide a cautionary note on therapeutic efforts to deplete androgens concomitantly with enzalutamide treatment as this may accentuate AR agonism by enzalutamide in tumors harboring AR F876L mutations. Finally, targeting critical AR transcriptional co-activators is a promising strategy to suppress mutant AR F876L function irrespective of whether the AR agonist is androgens or enzalutamide. Citation Format: Daniel Coleman, Katy Van Hook, Robert Lisac, Carly King, Nicholas Wang, Jacob Schwartzman, Martin Gleave, Lina Gao, Joshua Urrutia, Laura Heiser, Joshi J. Alumkal. Androgens interfere with enzalutamide agonism of mutant F876L androgen receptor. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3592. doi:10.1158/1538-7445.AM2015-3592
- 1 August 2015
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 75 (15_Supplem) , 3592
Abstract 3592: Androgens interfere with enzalutamide agonism of mutant F876L androgen receptor
Multiple lines of evidence demonstrate that castration-resistant prostate cancers (CRPCs) remain reliant on androgens that activate the androgen receptor (AR). Treatment with the novel anti-androgen enzalutamide improves both progression-free and overall survival in CRPC patients (Beer, 2014, Scher, 2012). However, progression is universal. Recently, F876L mutations in the AR ligand binding domain have been described (Balbas, 2013, Korpal, 2013, Joseph, 2013). This mutation confers resistance to enzalutamide treatment and in some cases converts enzalutamide to an AR agonist in pre-clinical studies (Balbas, 2013, Korpal, 2013, Joseph, 2013). Clinical studies demonstrate that ∼10% of patients harbor F876L mutations after treatment with novel anti-androgens (Joseph, 2013). However, anti-androgen withdrawal effects (PSA responses) after discontinuing enzalutamide are rarely seen clinically (Rodriguez-Vida, 2014). An enzalutamide-resistant cell line was developed after chronic treatment of LNCaP cells in vivo. We found that this resistant cell line was dependent on AR expression for survival and that this cell line harbored an AR F876L mutation. When these resistant cells were cultured in complete serum, enzalutamide treatment did not lead to agonistic effects. However, enzalutamide treatment of these resistant cells or cell lines with ectopic expression of AR F876L cultured in androgen-depleted serum led to a significant agonistic effect - an effect that was attenuated by the addition of androgens to culture. Finally, prior work and our own demonstrated that F876L mutant and wild-type AR activate similar pathways (Joseph, 2013). Therefore, we determined if suppression of previously described transcriptional co-activators of wild-type AR also blocked AR F876L function. We found several targetable AR co-activators that met that standard. Our data demonstrate that androgens interfere with enzalutamide-induced agonism of F876L mutant AR. Because androgens persist in enzalutamide-resistant CRPC, AR activation by androgens, rather than enzalutamide, may explain why enzalutamide discontinuation does not lead to anti-androgen withdrawal effects clinically. Further, our results provide a cautionary note on therapeutic efforts to deplete androgens concomitantly with enzalutamide treatment as this may accentuate AR agonism by enzalutamide in tumors harboring AR F876L mutations. Finally, targeting critical AR transcriptional co-activators is a promising strategy to suppress mutant AR F876L function irrespective of whether the AR agonist is androgens or enzalutamide. Citation Format: Daniel Coleman, Katy Van Hook, Robert Lisac, Carly King, Nicholas Wang, Jacob Schwartzman, Martin Gleave, Lina Gao, Joshua Urrutia, Laura Heiser, Joshi J. Alumkal. Androgens interfere with enzalutamide agonism of mutant F876L androgen receptor. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3592. doi:10.1158/1538-7445.AM2015-3592
- 1 August 2015
- Published by American Association for Cancer Research (AACR)
- Vol. 75 (15 Supplem) , 731
Abstract 731: Integrative genomic analysis to identify emergent enzalutamide resistance mechanisms in castration-resistant prostate cancer
Background: Multiple lines of evidence demonstrate that castration-resistant prostate cancers (CRPCs) remain reliant on androgens that activate the androgen receptor. Treatment with the novel anti-androgen enzalutamide improves progression-free survival and overall survival in CRPC patients; however, nearly 50% of patients never respond, and progression is universal (Beer, 2014, Scher, 2012). Mechanisms of enzalutamide resistance are largely unknown and few treatments exist for enzalutamide-resistant CRPC. Recent work demonstrates that CRPC tumors harbor countless genomic aberrations that control many hallmarks of cancer (Grasso, 2012, Hanahan and Weinberg, 2011). Based on our prior work (Heiser, 2012, Vaske, 2010), we hypothesize that these aberrations operate in concert to drive enzalutamide resistance and influence specific cancer hallmarks. Methods: We performed genomic studies using paired enzalutamide-sensitive and resistant LNCaP cell models. After transcriptional and copy number profiling, we performed an integrative pathway-informed PARADIGM analysis to identify differentially regulated cellular networks (Heiser, 2012, Vaske, 2010). These large-scale networks underwent regression analysis to identify sub-networks associated with acquired resistance. Genes residing within significant sub-networks were nominated for functional validation studies with RNAi or existing therapeutic compounds that impinge upon significant sub-networks in resistant models. Results: We used PARADIGM to compare the genomic alterations between the parental and enzalutamide-resistant cell line models and identified critical deregulated networks that may be targeted therapeutically. Currently, we are applying this same PARADIGM analysis to additional model systems and metastatic patient tumors obtained prior to treatment and at the time of disease progression through a West Coast Dream Team prospective enzalutamide clinical trial. Conclusions: PARADIGM integrative genomic analysis identifies specific sub-networks that contribute to enzalutamide resistance. A predicted outcome of our efforts is the development of rationally designed clinical trials with specific enzalutamide drug combinations in distinct molecular subsets of CRPC patients in the near-term. Citation Format: Josha Woodward, Carly King, Daniel Coleman, Robert Lisac, Jacob Schwartzman, Nicholas Wang, Martin Gleave, Joe Gray, George Thomas, Tomasz M. Beer, Katy Van Hook, Robert Baertsch, Ted Goldstein, Josh Stuart, Lina Gao, Joshua Urrutia, Laura Heiser, Joshi J. Alumkal. Integrative genomic analysis to identify emergent enzalutamide resistance mechanisms in castration-resistant prostate cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 731. doi:10.1158/1538-7445.AM2015-731
- 1 August 2015
- Published by American Association for Cancer Research (AACR)
- Vol. 75 (15 Supplem) , 731
Abstract 731: Integrative genomic analysis to identify emergent enzalutamide resistance mechanisms in castration-resistant prostate cancer
Background: Multiple lines of evidence demonstrate that castration-resistant prostate cancers (CRPCs) remain reliant on androgens that activate the androgen receptor. Treatment with the novel anti-androgen enzalutamide improves progression-free survival and overall survival in CRPC patients; however, nearly 50% of patients never respond, and progression is universal (Beer, 2014, Scher, 2012). Mechanisms of enzalutamide resistance are largely unknown and few treatments exist for enzalutamide-resistant CRPC. Recent work demonstrates that CRPC tumors harbor countless genomic aberrations that control many hallmarks of cancer (Grasso, 2012, Hanahan and Weinberg, 2011). Based on our prior work (Heiser, 2012, Vaske, 2010), we hypothesize that these aberrations operate in concert to drive enzalutamide resistance and influence specific cancer hallmarks. Methods: We performed genomic studies using paired enzalutamide-sensitive and resistant LNCaP cell models. After transcriptional and copy number profiling, we performed an integrative pathway-informed PARADIGM analysis to identify differentially regulated cellular networks (Heiser, 2012, Vaske, 2010). These large-scale networks underwent regression analysis to identify sub-networks associated with acquired resistance. Genes residing within significant sub-networks were nominated for functional validation studies with RNAi or existing therapeutic compounds that impinge upon significant sub-networks in resistant models. Results: We used PARADIGM to compare the genomic alterations between the parental and enzalutamide-resistant cell line models and identified critical deregulated networks that may be targeted therapeutically. Currently, we are applying this same PARADIGM analysis to additional model systems and metastatic patient tumors obtained prior to treatment and at the time of disease progression through a West Coast Dream Team prospective enzalutamide clinical trial. Conclusions: PARADIGM integrative genomic analysis identifies specific sub-networks that contribute to enzalutamide resistance. A predicted outcome of our efforts is the development of rationally designed clinical trials with specific enzalutamide drug combinations in distinct molecular subsets of CRPC patients in the near-term. Citation Format: Josha Woodward, Carly King, Daniel Coleman, Robert Lisac, Jacob Schwartzman, Nicholas Wang, Martin Gleave, Joe Gray, George Thomas, Tomasz M. Beer, Katy Van Hook, Robert Baertsch, Ted Goldstein, Josh Stuart, Lina Gao, Joshua Urrutia, Laura Heiser, Joshi J. Alumkal. Integrative genomic analysis to identify emergent enzalutamide resistance mechanisms in castration-resistant prostate cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 731. doi:10.1158/1538-7445.AM2015-731
- Open Access
- 21 May 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (5) , e63563
Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation
The androgen receptor (AR) is the principal therapeutic target in prostate cancer. For the past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus. However, some patients do not benefit, and those tumors that do initially respond to ADT eventually progress. One recently described mechanism of such an effect is growth and survival-promoting effects of the AR that are exerted independently of the AR ligands, testosterone and dihydrotestosterone. However, specific ligand-independent AR target genes that account for this effect were not well characterized. We show here that c-Myc, which is a key mediator of ligand-independent prostate cancer growth, is a key ligand-independent AR target gene. Using microarray analysis, we found that c-Myc and AR expression levels strongly correlated with each other in tumors from patients with castration-resistant prostate cancer (CRPC) progressing despite ADT. We confirmed that AR directly regulates c-Myc transcription in a ligand-independent manner, that AR and c-Myc suppression reduces ligand-independent prostate cancer cell growth, and that ectopic expression of c-Myc attenuates the anti-growth effects of AR suppression. Importantly, treatment with the bromodomain inhibitor JQ1 suppressed c-Myc function and suppressed ligand-independent prostate cancer cell survival. Our results define a new link between two critical proteins in prostate cancer – AR and c-Myc – and demonstrate the potential of AR and c-Myc-directed therapies to improve prostate cancer control.
- 21 May 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (5) , e63563
Open AccessAndrogen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation
The androgen receptor (AR) is the principal therapeutic target in prostate cancer. For the past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus. However, some patients do not benefit, and those tumors that do initially respond to ADT eventually progress. One recently described mechanism of such an effect is growth and survival-promoting effects of the AR that are exerted independently of the AR ligands, testosterone and dihydrotestosterone. However, specific ligand-independent AR target genes that account for this effect were not well characterized. We show here that c-Myc, which is a key mediator of ligand-independent prostate cancer growth, is a key ligand-independent AR target gene. Using microarray analysis, we found that c-Myc and AR expression levels strongly correlated with each other in tumors from patients with castration-resistant prostate cancer (CRPC) progressing despite ADT. We confirmed that AR directly regulates c-Myc transcription in a ligand-independent manner, that AR and c-Myc suppression reduces ligand-independent prostate cancer cell growth, and that ectopic expression of c-Myc attenuates the anti-growth effects of AR suppression. Importantly, treatment with the bromodomain inhibitor JQ1 suppressed c-Myc function and suppressed ligand-independent prostate cancer cell survival. Our results define a new link between two critical proteins in prostate cancer – AR and c-Myc – and demonstrate the potential of AR and c-Myc-directed therapies to improve prostate cancer control.